ID: ALA5173559

Max Phase: Preclinical

Molecular Formula: C29H25Cl2N3O2

Molecular Weight: 518.44

Representations

Canonical SMILES:  C[C@H](NC(=O)[C@@H](c1cccnc1)N(C(=O)C(Cl)Cl)c1ccc(-c2ccccc2)cc1)c1ccccc1

Standard InChI:  InChI=1S/C29H25Cl2N3O2/c1-20(21-9-4-2-5-10-21)33-28(35)26(24-13-8-18-32-19-24)34(29(36)27(30)31)25-16-14-23(15-17-25)22-11-6-3-7-12-22/h2-20,26-27H,1H3,(H,33,35)/t20-,26+/m0/s1

Standard InChI Key:  LEOCNIZCHQOMFL-RXFWQSSRSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 518.44

Molecular Weight (Monoisotopic): 517.1324

AlogP: 6.50

#Rotatable Bonds: 8

Polar Surface Area: 62.30

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.76

CX Basic pKa: 4.73

CX LogP: 5.76

CX LogD: 5.76

Aromatic Rings: 4

Heavy Atoms: 36

QED Weighted: 0.27

Np Likeness Score: -1.05

References

1. Gai C, Harnor SJ, Zhang S, Cano C, Zhuang C, Zhao Q..  (2022)  Advanced approaches of developing targeted covalent drugs.,  13  (12.0): [PMID:36561076] [10.1039/d2md00216g]

2. Gao S, Song L, Claff T, Woodson M, Sylvester K, Jing L, Weiße RH, Cheng Y, Sträter N, Schäkel L, Gütschow M, Ye B, Yang M, Zhang T, Kang D, Toth K, Tavis J, Tollefson AE, Müller CE, Zhan P, Liu X..  (2022)  Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.,  65  (24.0): [PMID:36475694] [10.1021/acs.jmedchem.2c01716]

3. Chen R, Gao Y, Liu H, Li H, Chen W, Ma J..  (2023)  Advances in research on 3C-like protease (3CL^pro) inhibitors against SARS-CoV-2 since 2020.,  14  (1): [PMID:36760740] [10.1039/d2md00344a]

Source

Source(1):

• Scientific Literature